Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief

Trial Profile

Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Trametinib (Primary)
  • Indications Plexiform neurofibroma
  • Focus Therapeutic Use
  • Acronyms plexifpc
  • Most Recent Events

    • 21 Dec 2018 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
    • 21 Dec 2018 Planned primary completion date changed from 1 May 2022 to 1 Jul 2022.
    • 26 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top